PhaseBio Pharmaceuticals (stock symbol: PHAS) Logo in transparent PNG format

PhaseBio Pharmaceuticals Logo large

PhaseBio Pharmaceuticals Logo icon format

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

  • Website domain: phasebio.com
  • Employees: 60
  • Marketcap: $9.39 Million USD

Page last updated on:

November 22nd, 2020

Categories: